Published in Int J Cancer on October 22, 1999
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol (2012) 2.94
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest (2005) 2.20
Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One (2012) 2.14
An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One (2010) 2.08
The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One (2012) 2.05
Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol (2005) 1.85
Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract (2015) 1.42
Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets (2011) 1.38
The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med (2010) 1.33
Control of the immune response by pro-angiogenic factors. Front Oncol (2014) 1.26
Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br J Cancer (2006) 1.24
Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Cancer Res (2009) 1.19
The NF-κB/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1β. Cancer Microenviron (2009) 1.13
Inflammation and cancer. World J Gastrointest Surg (2012) 1.12
Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum Reprod Update (2012) 1.06
Comparative immunohistochemical analysis of angiogenesis and mast cell density in oral normal mucosa and squamous cell carcinoma. Dent Res J (Isfahan) (2012) 1.05
Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res (2013) 1.04
Macrophages promote tumour growth and liver metastasis in an orthotopic syngeneic mouse model of colon cancer. Int J Colorectal Dis (2013) 1.04
VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia (2014) 0.99
A digest on the role of the tumor microenvironment in gastrointestinal cancers. Cancer Microenviron (2010) 0.97
Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med (2005) 0.97
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother (2011) 0.90
Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol (2002) 0.88
Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chin J Cancer (2011) 0.87
Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection. Mol Pharm (2006) 0.81
Correlation of tumor-associated macrophages and clinicopathological factors in Wilms tumor. Vasc Cell (2013) 0.79
Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer (2003) 0.79
Tumor angiogenesis, macrophages and mast cell microdensities in endometrioid endometrial carcinoma. Oncol Lett (2013) 0.79
Myeloid cells in cancer progression: unique subtypes and their roles in tumor growth, vascularity, and host immune suppression. Cancer Microenviron (2010) 0.78
¹¹¹In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages. Eur J Nucl Med Mol Imaging (2015) 0.78
Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer. Biomark Cancer (2015) 0.77
Activating transcription factor 4 promotes angiogenesis of breast cancer through enhanced macrophage recruitment. Biomed Res Int (2015) 0.76
Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med (2016) 0.75
One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer Metastasis Rev (2016) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res (2001) 6.78
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A (2009) 2.72
Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer (2006) 1.80
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer (2001) 1.63
Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol (2001) 1.49
Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer (2009) 1.45
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer (2009) 1.41
Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res (2000) 1.26
Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat (2013) 1.26
Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res (2000) 1.20
Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol (1999) 1.17
Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur J Surg (1993) 1.06
High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer (2011) 1.05
Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol (1999) 1.05
Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiol Biomarkers Prev (2001) 1.03
Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology (2008) 1.03
Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer (1997) 1.02
Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer (2008) 1.02
Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology (2004) 0.99
Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer (2005) 0.98
Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res (2000) 0.97
A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer (2001) 0.96
Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome. Br J Cancer (2012) 0.96
Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast (2012) 0.95
Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res (2000) 0.95
Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anticancer Res (2001) 0.94
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer (2003) 0.93
Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res (1996) 0.93
Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania. Oncol Rep (2000) 0.93
Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. Int J Cancer (1998) 0.92
Lymphatic vessel density and prognosis in cutaneous melanoma. Br J Cancer (2004) 0.92
Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer (1992) 0.91
Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol (2008) 0.89
Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int J Cancer (1993) 0.88
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer (2003) 0.88
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer (2012) 0.87
Independent prognostic importance of vascular invasion in nodular melanomas. Cancer (1996) 0.86
Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene (2001) 0.86
Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res (1998) 0.86
Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. Int J Cancer (1990) 0.86
Lifestyle and mortality among Norwegian men. Prev Med (1989) 0.85
Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer (2000) 0.85
Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer (1997) 0.84
Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol (1991) 0.83
Geographic patterns and trends in the incidence of thyroid cancer in Norway 1970-1986. Cancer Detect Prev (1990) 0.83
Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene. Clin Cancer Res (2000) 0.83
Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr Med J (2001) 0.83
Survival and prognostic factors in differentiated thyroid cancer--a multivariate analysis of 1,055 cases. Br J Cancer (1989) 0.82
Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer (1998) 0.82
Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. Int J Cancer (1997) 0.82
P53 immunostaining in melanocytic lesions. Eur J Cancer (1993) 0.80
Thyroid cancer in children in Norway 1953-1987. Eur J Cancer (1993) 0.80
Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol (1997) 0.80
Poorly differentiated thyroid carcinoma--it is important. Am J Surg Pathol (2000) 0.79
Analyses of chromium and nickel in human pulmonary tissue. Investigations in lung cancer patients and a control population under special consideration of medical expertise aspects. Int Arch Occup Environ Health (1989) 0.79
Elevated 1,25-dihydroxyvitamin D and normocalcaemia in presumed familial Williams syndrome. Clin Genet (1987) 0.79
Papillary thyroid carcinoma with lipomatous stroma. Am J Surg Pathol (1997) 0.79
Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Res (2001) 0.78
Thyroid carcinoma: results from surgical treatment in 211 consecutive patients. Eur J Surg (1991) 0.78
Cytoplasmic localization of EGF receptor in papillary thyroid carcinomas: association with the 150-kDa receptor form. Int J Cancer (1996) 0.78
Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. Urol Oncol (2011) 0.77
Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res (2002) 0.77
Expression of heregulins and associations with the ErbB family of tyrosine kinase receptors in papillary thyroid carcinomas. Int J Cancer (2000) 0.77
Provocation of thyroid neoplasms in female Wistar rats fed n-3 or n-6 fatty acids in the feed. Thyroidology (1990) 0.77
Increased risk of thyroid cancer among Norwegian women married to fishery workers--a retrospective cohort study. Br J Cancer (1997) 0.77
Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. Int J Gynecol Cancer (2004) 0.76
Poorer survival of nulliparous women with endometrial carcinoma. Cancer (1998) 0.76
Peritoneal carcinosis in apparently benign cortisol producing adrenal adenoma ≥ 5 cm in diameter: the need of regular postoperative surveillance. Exp Clin Endocrinol Diabetes (2012) 0.76
Melanoma and sun exposure. Lancet (1995) 0.75
Re: "Incidence of thyroid cancer in New Caledonia, South Pacific, during 1985-1992". Am J Epidemiol (1996) 0.75
[Mortality of patients with differentiated thyroid carcinoma in Norway. The influence of sex, age, tumor stage, histologic type and residence at the time of diagnosis]. Tidsskr Nor Laegeforen (1989) 0.75
Malignant melanoma of the skin. Changing clinical stage at presentation, 1955-1979. Oncology (1987) 0.75
Adrenal gland influence on immune disturbances induced by neonatal exposure to diethylstilbestrol. Cell Mol Biol (1982) 0.75
Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncol (1996) 0.75
Squamous cell carcinoma of the urinary bladder. Scand J Urol Nephrol (1991) 0.75
Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer (1998) 0.75
Seasonal variation in melanoma progress. J Natl Cancer Inst (1995) 0.75
[Diagnostic molecular biology in solid tumors--thyroid gland]. Tidsskr Nor Laegeforen (1998) 0.75
[Increased incidence of thyroid cancer among Norwegian women married to fishermen]. Tidsskr Nor Laegeforen (1998) 0.75
Ploidy and proliferation rates in carcinomas of the breast in Tanzania. East Afr Med J (1994) 0.75
Fetal heart block, anti-SSA and anti-SSB antibodies. Association with intra-uterine growth retardation, fetal death and lupus anticoagulant. Acta Obstet Gynecol Scand (1987) 0.75
[Differences in mortality among Norwegian men. The role of smoking, alcohol consumption, physical activity and selected dietary habits]. Tidsskr Nor Laegeforen (1986) 0.75
[Malignant melanoma--amelanotic type]. Tidsskr Nor Laegeforen (1987) 0.75
Lack of immunoreactivity between human monoclonal HLA-B27 antibodies and Yersinia enterocolitica strains from arthritic patients. Scand J Rheumatol (1989) 0.75
Clinicopathological characteristics of melanomas of the hand. J Hand Surg Br (1999) 0.75
Enhanced expression of EGF receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours. Virchows Arch (1999) 0.75
Prognostic importance of tumor diameter in nodular melanomas. Ann Plast Surg (1997) 0.75
[Malignant melanoma of the skin]. Tidsskr Nor Laegeforen (1987) 0.75
[Malignant melanoma. Unknown primary tumor and long survival--2 rare case reports]. Tidsskr Nor Laegeforen (1987) 0.75